AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00022581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03468478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus combined to reduced dose of tacrolimus
Study NCT03468478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus combined to reduced dose of tacrolimus
Study NCT03468478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid
Description: Control arm: mycophenolate combined to regular tacrolimus
Study NCT00553488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro (Humalog)
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
Study NCT02233699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501
Study NCT02233699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00827710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: point of care patient report cards
Description: gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
Study NCT00827710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider performance report card
Description: Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
Study NCT01268852 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Damon self ligating orthodontic bracket
Description: Orthodontic treatment with Damon self ligating bracket
Study NCT01268852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insignia self ligating orthodontic bracket
Description: Orthodontic treatment with Insignia self ligating bracket
Study NCT03854721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAX014
Description: Solution for intravesical infusion, 3.33x10\^10 rBMCs per vial
Study NCT06171854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: cabozantinib in patients with refractory mCRC
Study NCT02050334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC100
Description: CC100 reconstituted in diluent
Study NCT02050334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diluent. Amount to match CC100 dose.
Study NCT01583413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daily SAT & SBT
Description: Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
Study NCT01290510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid sodium salt
Description: Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
Study NCT02410447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocused shock wave therapy (DUOLITH® SD1)
Study NCT01625871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tablets artemether/lumefantrine
Description: six doses of oral tablets of artemether/lumefantrine
Study NCT03869762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xgeva
Description: Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer induced bone destruction.
Study NCT03869762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xtandi
Description: Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.~Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression.
Study NCT03578627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BioBehavioral Intervention
Description: Psychological (stress and quality of life), behavioral (health behaviors and compliance), and biologic (neuroendocrine and immune) factors, and pathways by which health outcomes (e.g. disease endpoints-recurrence, disease free interval) might be affected.
Study NCT02788721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451 single dose
Description: GLPG2451 oral suspension, single ascending doses, daily
Study NCT02788721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral suspension, daily
Study NCT02983760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Planar V/Q-based strategy
Description: Strategy based on planar pulmonary scintigraphy
Study NCT02983760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CTPA-based strategy
Description: Strategy based on pulmonary angiography
Study NCT02983760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V/Q SPECT-based strategy
Description: Strategy based on pulmonary tomoscintigraphy
Study NCT02990130 — intervention group
Intervention type: OTHER
Intervention: Observational
Study NCT03295734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Twice weekly centered based aerobic exercise + 3/week home-based walking
Study NCT03295734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 4 mg qd titrated to 8 mg qd perindopril
Study NCT03295734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50 mg qd titrated to 100 qd losartan
Study NCT03295734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: 12.5 mg qd titrated to 25 qd HCTZ
Study NCT03124160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mona Lisa® NT Cu380 Mini
Description: copper intrauterine device
Study NCT03124160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ParaGard® TCu380A
Description: copper intrauterine device
Study NCT00921661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0005 (aflibercept)
Description: IV infusion
Study NCT01750060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT01750060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT01750060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study NCT01750060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Study NCT04701450 — intervention group
Intervention type: OTHER
Intervention: digital consent
Description: the patient's medical history is taken in a digital survey, information about the anaesthetic procedure is aided by video material
Study NCT02778152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser depilation
Description: Laser depilation of natal cleft (pilonidal region)
Study NCT02213315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg Mavrilimumab
Description: 100mg Mavrilimumab
Study NCT02213315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150mg mavrilimumab
Description: 150mg mavrilmumab
Study NCT02213315 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01272908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1000 mg intravenously on Days 1 and 15
Study NCT02482142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Effect of phosphorus
Description: Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
Study NCT02482142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effect of phosphorus
Description: Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
Study NCT00527826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol / Fluticasone (50/500 µg) BID fixed combination
Description: comparator
Study NCT01064648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given orally
Study NCT01064648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01064648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT01064648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01064648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01064648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT01064648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT01064648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given orally
Study NCT06748040 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic (PGx) testing
Description: Participants will be randomized to immediate versus delayed return of PGx results.
Study NCT00527826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers
Description: comparator
Study NCT01222000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
Description: After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
Study NCT01144455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar (Gemcitabine)
Description: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
Study NCT06763510 — intervention group
Intervention type: DRUG
Intervention: Chirocaine
Description: Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Isobaric levobupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
Study NCT06763510 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine
Description: Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Hyperbaric bupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
Study NCT04225442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fatty meal to challenge the physiological chronobiome in healthy young and old
Description: The intervention consists of a fatty meal
Study NCT00109174 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3T and 7T device
Description: 3T and 7T device
Study NCT03255746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Enhancement
Description: This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
Study NCT03255746 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
Study NCT02259855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02259855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02259855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Study NCT02259855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT04216576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Drug Diary
Description: Participants will receive and use a paper Drug Diary and a paper medication calendar.
Study NCT04216576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OhMD APP
Description: Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication
Study NCT02872532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular tissue cryopreservation
Description: Testicular tissue will be removed
Study NCT03899792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-292
Description: Oral LOXO-292
Study NCT00682318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days
Study NCT00682318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Safflower Oil
Description: Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
Study NCT00682318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution
Study NCT00682318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution
Study NCT00682318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b.
Study NCT00682318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-6 polyunsaturated fatty acid
Description: Part 2b:~Control omega-6 fatty acid alimentary diet (\<130 mg/day EPA/DHA)
Study NCT02678455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV005 vaccine
Description: Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.
Study NCT02678455 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered by subcutaneous injection
Study NCT04445337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: An injection of local anesthetic into the front of the neck. SGB involves placing a small tube into the front of your neck, toward nerves at the back of your neck. This is done with the help of an x-ray machine or ultrasound device. The tube is left in place so you can get medication thru it for five days. Then the tube is taken out.~The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block. These medications are approved by the Food and Drug Administration (FDA).
Study NCT03572881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial mapping
Description: An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.
Study NCT01976247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Focused Ultrasound Device
Study NCT01976247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive Cryolipolysis Device
Study NCT04161651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eversense
Description: eversense CGM
Study NCT04239599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT Radiation treatment
Study NCT04239599 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated IMRT Radiation treatment
Study NCT02895919 — intervention group
Intervention type: OTHER
Intervention: Culture
Description: culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
Study NCT04647747 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self measurement with pulse oximeter
Description: Participant will measure peripheral saturation at home, conduct physiotherapy if desaturation occurs, and contact hospital if desatuation persists
Study NCT03816761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart
Description: In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.
Study NCT03816761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet™
Description: The bionic pancreas including pigtail adapters, used in insulin-only configuration
Study NCT01030393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotrophin
Description: intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
Study NCT02859077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: EGFR-TKI (gefitinib)
Study NCT02859077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy（pemetrexed/gemcitabine）
Description: Chemotherapy (pemetrexed/gemcitabine)
Study NCT02859077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy（carboplatin）
Description: Chemotherapy（carboplatin）
Study NCT01174069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NOTES assisted laparoscopic cholecystectomy
Description: Surgical removal of the gallbladder using endoscopic instruments.
Study NCT04358432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection
Study NCT04358432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administered by subcutaneous injection
Study NCT04358432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies
Study NCT04358432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies